Linx Procedure denials in California external review

What the reviewers wrote

Where the denial was overturned

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for LINX procedure. The provider noted that this patient presents with typical gastroesophageal reflux disease (GERD) symptoms, an abnormal pH study, and intolerance to PPI therapy due to PPI associated candida esophagitis. In addition and per study authors, the patient’s records document that there are no findings of a large hiatal hernia, severe esophagitis, Barrett’s esophagus, obesity, esophageal dysmotility, or prior upper gastrointestinal tract surgery. On review of the medical literature, the LINX reflux management system has been shown to be superior to twice daily proton pump inhibitor therapy and Nissen fundoplication.

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for LINX procedure. In this case, the patient presents with symptoms of gastroesophageal reflux disease (GERD) and esophagitis. The records show that the patient has no motility disorder and no obstruction. The records also show that he has minimal to no hiatal hernia. The LINX procedure/magnetic sphincter augmentation (MSA) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with GERD. The LINX procedure has been in use for more than a decade with documented success rates equivalent to and not inferior to traditional surgery. Overall, the use of the LINX procedure is supported by the medical literature in this patient’s clinical setting.

Where the denial was upheld

Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for LINX procedure. Findings: The physician reviewer found that The U.S. Food and Drug Administration (FDA) approved the LINX procedure for lower esophageal sphincter augmentation. Eligible patients for the procedure include those with inadequate symptom control with acid suppression therapy, including those patients with mild to moderate gastroesophageal reflux disease (GERD) and a hiatal hernia less than 3 cm. A recent retrospective study comparing the LINX procedure with laparoscopic fundoplication concluded that GERD patients had similar control of reflux symptoms after both LINX and fundoplication. The authors noted that the inabilities to belch and vomit were significantly fewer with LINX, along with a significantly lower incidence of severe gas-bloat symptoms.

Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for the LINX procedure (CPT 43284). Lipham and colleagues note in a multicenter, prospective, single-arm study of 44 patients, that sphincter augmentation with the LINX Reflux Management System provided long-term clinical benefits without safety issues, as demonstrated by reduced esophageal acid exposure, improved quality of life related to gastroesophageal reflux disease (GERD), and cessation of dependence on proton-pump inhibitors (PPIs), with minimal side effects and no safety issues. However, Sheu and Rattner note that the long-term safety and efficacy of LINX — both alone and compared to current GERD therapies — remains to be determined. Bauer and colleagues note the possibility of adverse events, including erosion through the esophagus. While the U.S.

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Linx Procedure, then check the rights and deadlines that apply to your plan.